← All trials
NCT03575234
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- Brooklyn ImmunotherapeuticsCollaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- Emory UniversityOfficial
- Bristol-Myers SquibbCollaborator
- Emory UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.